EXECUTION VERSION EXCLUSIVE LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF CHICAGO AND CALIDI BIOTHERAPEUTICS FOR ONCOLYTIC VIROTHERAPY TECHNOLOGYBiotherapeutics for Oncolytic Virotherapy Technology • April 13th, 2023 • First Light Acquisition Group, Inc. • Biological products, (no disgnostic substances)
This License Agreement (“Agreement”), dated July 22, 2021 (the “Effective Date”), is between The University of Chicago, an Illinois not-for-profit corporation (“University”), and Calidi Biotherapeutics, a Nevada corporation, having an address at 11011 North Torrey Pines Road, Suite 200 La Jolla, CA 92037, USA (“Company”). Each hereunder may be referred to separately as the “Party”, or together as the “Parties”.
